These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35903020)

  • 21. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives.
    Facciorusso A
    Curr Diabetes Rev; 2013 Sep; 9(5):382-6. PubMed ID: 23845075
    [TBL] [Abstract][Full Text] [Related]  

  • 22.  Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries.
    Seyda Seydel G; Kucukoglu O; Altinbasv A; Demir OO; Yilmaz S; Akkiz H; Otan E; Sowa JP; Canbay A
    Ann Hepatol; 2016; 15(5):662-72. PubMed ID: 27493104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
    Nguyen XK; Zhang J; Chin KL; Bloom S; Nicoll AJ
    Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease.
    Teng PC; Huang DQ; Lin TY; Noureddin M; Yang JD
    Gut Liver; 2023 Jan; 17(1):24-33. PubMed ID: 36530125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of non-alcoholic fatty liver disease in Asia.
    Wong SW; Chan WK
    Indian J Gastroenterol; 2020 Feb; 39(1):1-8. PubMed ID: 32152903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
    Marengo A; Rosso C; Bugianesi E
    Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
    Pocha C; Kolly P; Dufour JF
    Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
    Wong CR; Nguyen MH; Lim JK
    World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
    Golabi P; Rhea L; Henry L; Younossi ZM
    Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
    Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
    Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases.
    Shin HS; Jun BG; Yi SW
    Clin Mol Hepatol; 2022 Oct; 28(4):773-789. PubMed ID: 35934813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
    Reeves HL; Zaki MY; Day CP
    Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
    Michel M; Kalliga E; Labenz C; Straub BK; Wörns MA; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):57-62. PubMed ID: 31931541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    Lange NF; Radu P; Dufour JF
    J Hepatol; 2021 Nov; 75(5):1217-1227. PubMed ID: 34339764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology and risk-stratification of NAFLD-associated HCC.
    Ioannou GN
    J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.
    Loomba R; Lim JK; Patton H; El-Serag HB
    Gastroenterology; 2020 May; 158(6):1822-1830. PubMed ID: 32006545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.